15 Small-Cap Healthcare Stocks Hedge Funds Are Buying

6. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

No. of Hedge Fund Holders: 57

Market Capitalization: $11.73 Billion

Analyst Upside: 37.11%

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company engaged in developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Neurocrine Biosciences has a robust pipeline focused on depression, epilepsy, and schizophrenia, working in collaboration with Takeda, Idorsia, and Voyager.

On May 6, Needham raised its price target on NBIX from $138 to $139, giving a Buy rating to the stock. The price update reflects Neurocrine Biosciences’ positive outlook for Ingrezza, NBIX’s flagship product for the treatment of tardive dyskinesia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported strong quarterly results in Q1 2025. The company noted record new patient stats for INGREZZA, indicating robust market demand. On top of that, the company launched CRENESSITY, which achieved nearly $15 million in net revenue. Neurocrine expanded formulary coverage for INGREZZA in Medicare Part D, which allowed easy access for patients and led to higher turnout. The company holds a solid financial position with almost $1.8 billion in cash.